The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

The best metric is not weight, but a particularly toxic kind of fat.

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Are you noticing the days are starting to seem longer, yet secretly worrying that your tiredness is really taking the toll on ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...